These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20029953)

  • 1. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.
    Tefferi A; Siragusa S; Hussein K; Schwager SM; Hanson CA; Pardanani A; Cervantes F; Passamonti F
    Am J Hematol; 2010 Jan; 85(1):14-7. PubMed ID: 20029953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Karyotype complements the International Prognostic Scoring System for primary myelofibrosis.
    Hussein K; Huang J; Lasho T; Pardanani A; Mesa RA; Williamson CM; Ketterling RP; Hanson CA; Van Dyke DL; Tefferi A
    Eur J Haematol; 2009 Apr; 82(4):255-9. PubMed ID: 19215287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.
    Tefferi A; Mesa RA; Pardanani A; Hussein K; Schwager S; Hanson CA; Steensma DP
    Am J Hematol; 2009 May; 84(5):265-7. PubMed ID: 19396855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
    Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM
    Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.
    Patnaik MM; Caramazza D; Gangat N; Hanson CA; Pardanani A; Tefferi A
    Eur J Haematol; 2010 Feb; 84(2):105-8. PubMed ID: 19895568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.
    Bacigalupo A; Soraru M; Dominietto A; Pozzi S; Geroldi S; Van Lint MT; Ibatici A; Raiola AM; Frassoni F; De Stefano F; Verdiani S; Casarino L; Barosi G
    Bone Marrow Transplant; 2010 Mar; 45(3):458-63. PubMed ID: 19718055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
    Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.
    Dingli D; Schwager SM; Mesa RA; Li CY; Tefferi A
    Cancer; 2006 Feb; 106(3):623-30. PubMed ID: 16369987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
    Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
    Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell transplantation for myelofibrosis: a report from two Canadian centers.
    Daly A; Song K; Nevill T; Nantel S; Toze C; Hogge D; Forrest D; Lavoie J; Sutherland H; Shepherd J; Hasegawa W; Lipton J; Messner H; Kiss T
    Bone Marrow Transplant; 2003 Jul; 32(1):35-40. PubMed ID: 12815476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
    Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
    Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
    Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
    Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.
    Gangat N; Caramazza D; Vaidya R; George G; Begna K; Schwager S; Van Dyke D; Hanson C; Wu W; Pardanani A; Cervantes F; Passamonti F; Tefferi A
    J Clin Oncol; 2011 Feb; 29(4):392-7. PubMed ID: 21149668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.
    Elena C; Passamonti F; Rumi E; Malcovati L; Arcaini L; Boveri E; Merli M; Pietra D; Pascutto C; Lazzarino M
    Haematologica; 2011 Jan; 96(1):167-70. PubMed ID: 20884708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features and prognostic factors in primary myelofibrosis patients under 45 years old].
    Lu L; Xiao ZJ; Chen HS; Lin H; Han ZC
    Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):281-4. PubMed ID: 15949290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
    Nevill TJ; Shepherd JD; Sutherland HJ; Abou Mourad YR; Lavoie JC; Barnett MJ; Nantel SH; Toze CL; Hogge DE; Forrest DL; Song KW; Power MM; Nitta JY; Dai Y; Smith CA
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):205-13. PubMed ID: 19167680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined stratification of refractory anemia according to both WHO and IPSS criteria has a prognostic impact and improves identification of patients who may benefit from stem cell transplantation.
    Cermák J; Vítek A; Michalová K
    Leuk Res; 2004 Jun; 28(6):551-7. PubMed ID: 15120930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.